Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials
The objective of this meta-analysis study was to evaluate the comparative efficacy of empagliflozin (25 mg) with placebo in the treatment and management of type 1 diabetes mellitus. This study is a meta-analysis, so an ethical statement is not required. Different databases and individual journal web...
Guardado en:
Autores principales: | Gillani Syed Wasif, Azhar Anam, Gulam Shabaz Mohiuddin, Gebreigziabher Fithawit Bahran, Rathore Hassaan Anwer |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Sciendo
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3c3b254bd1ef487aaed0f63d553cfbe4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
EL EFECTO PLACEBO EN LOS ENSAYOS CLÍNICOS CON ANTIDEPRESIVOS
por: Silva Ibarra,Hernán
Publicado: (2009) -
Empagliflozin in type 1 diabetes
por: Mathieu C, et al.
Publicado: (2019) -
Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
por: A. V. Simanenkova, et al.
Publicado: (2021) -
Empagliflozin: a new strategy for nephroprotection in diabetes
por: Anton Ivanovich Korbut, et al.
Publicado: (2017) -
Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
por: Vladimir V. Salukhov, et al.
Publicado: (2016)